Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

A padel version of the Ryder Cup will get underway in 2025 as the rapidly growing sport looks to make the most of its ...

America’s largest offshore wind and ocean renewables conference will be held in Virginia Beach, USA next year.

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...